Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $81.7 million.

  • Guided Therapeutics' Shares Outstanding (Weighted Average) rose 4321.6% to $81.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.7 million, marking a year-over-year increase of 4321.6%. This contributed to the annual value of $57.3 million for FY2024, which is 1214.14% up from last year.
  • As of Q3 2025, Guided Therapeutics' Shares Outstanding (Weighted Average) stood at $81.7 million, which was up 4321.6% from $78.8 million recorded in Q2 2025.
  • Guided Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $81.7 million for Q3 2025, and its period low was $49297.0 during Q1 2023.
  • For the 5-year period, Guided Therapeutics' Shares Outstanding (Weighted Average) averaged around $40.8 million, with its median value being $51.0 million (2023).
  • Per our database at Business Quant, Guided Therapeutics' Shares Outstanding (Weighted Average) soared by 26265683.22% in 2021 and then tumbled by 9976.17% in 2023.
  • Over the past 5 years, Guided Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $13.4 million in 2021, then soared by 142.99% to $32.5 million in 2022, then soared by 57.3% to $51.1 million in 2023, then increased by 12.14% to $57.3 million in 2024, then skyrocketed by 42.47% to $81.7 million in 2025.
  • Its last three reported values are $81.7 million in Q3 2025, $78.8 million for Q2 2025, and $68.3 million during Q1 2025.